When can Delstrigo go generic?
Delstrigo, an HIV-1 integrase inhibitor, is expected to face generic competition in the United States in 2032 [1]. This timeline is based on patent expiry dates.
What happens when Delstrigo goes generic?
When Delstrigo becomes available as a generic, it means that other pharmaceutical companies will be able to manufacture and market their own versions of the drug. Generic versions typically offer the same active ingredient and are therapeutically equivalent to the branded drug, but are usually sold at a lower cost [2]. This can increase access to treatment for patients and reduce healthcare expenses.
How does Delstrigo work?
Delstrigo is a combination medication containing three antiretroviral drugs: doravirine, lamivudine, and tenofovir disoproxil fumarate [3]. Doravirine inhibits the HIV-1 integrase enzyme, which is essential for the virus to replicate within host cells. Lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that also prevent viral replication [3].
What are the potential risks and side effects of Delstrigo?
Common side effects associated with Delstrigo include dizziness, fatigue, nausea, headache, and rash [3]. More serious but less common side effects can include liver problems, kidney problems, and lactic acidosis [3]. Patients with a history of kidney or liver disease should discuss this with their healthcare provider before starting Delstrigo [3].
How does Delstrigo compare to other HIV treatments?
Delstrigo is one of several combination antiretroviral therapies available for the treatment of HIV-1 infection. Other treatment options may involve different combinations of drugs, including integrase inhibitors, NRTIs, and non-nucleoside reverse transcriptase inhibitors (NNRTIs) [4]. The choice of treatment depends on individual patient factors, including viral load, CD4 count, drug resistance, and potential side effects [4]. Information on drug patents and exclusivity for various HIV medications can be found at DrugPatentWatch.com [1].
What is the pricing and accessibility of Delstrigo?
The pricing of branded medications like Delstrigo can be substantial. Once generic versions become available, the cost is expected to decrease significantly, potentially improving accessibility for a wider patient population.
Are there any pending legal challenges regarding Delstrigo's patents?
Information regarding specific patent litigation or challenges for Delstrigo is not readily available in the provided context. However, patent challenges are common in the pharmaceutical industry as companies seek to introduce generic alternatives earlier than the patent expiry date [1].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration. (2022). Generic Drugs.
[3] Merck & Co., Inc. (n.d.). DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) prescribing information.
[4] U.S. Department of Health and Human Services. (2023). HIV Treatment Guidelines.